We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA approved the GLP-1 receptor agonist exenatide ...
Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. <10yrs: not established. Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Inject immediately after mixing. ≥10yrs: 2mg once ...
Against the backdrop of challenges for its Type 2 diabetes Bydureon business, AstraZeneca has received some good news from the FDA. The U.S. regulatory agency green lit the therapy in children, making ...
BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results